In This Article:
The Canadian market has been navigating a complex landscape marked by fluctuating bond yields and evolving interest rate expectations, which have influenced stock valuations. Amidst these dynamics, penny stocks—typically smaller or newer companies—continue to capture investor interest due to their affordability and potential for growth. Despite being an older term, the allure of penny stocks remains strong as they can offer compelling opportunities when supported by solid financial health.
Top 10 Penny Stocks In Canada
Name | Share Price | Market Cap | Financial Health Rating |
Silvercorp Metals (TSX:SVM) | CA$4.45 | CA$985.56M | ★★★★★★ |
Mandalay Resources (TSX:MND) | CA$4.18 | CA$388.78M | ★★★★★★ |
Findev (TSXV:FDI) | CA$0.465 | CA$14.32M | ★★★★★★ |
Pulse Seismic (TSX:PSD) | CA$2.41 | CA$123.54M | ★★★★★★ |
PetroTal (TSX:TAL) | CA$0.70 | CA$669.36M | ★★★★★★ |
Foraco International (TSX:FAR) | CA$2.35 | CA$229.35M | ★★★★★☆ |
NamSys (TSXV:CTZ) | CA$1.11 | CA$29.82M | ★★★★★★ |
East West Petroleum (TSXV:EW) | CA$0.04 | CA$3.17M | ★★★★★★ |
Hemisphere Energy (TSXV:HME) | CA$1.83 | CA$179.61M | ★★★★★☆ |
Tornado Infrastructure Equipment (TSXV:TGH) | CA$1.03 | CA$137.56M | ★★★★★☆ |
Click here to see the full list of 936 stocks from our TSX Penny Stocks screener.
Here we highlight a subset of our preferred stocks from the screener.
PharmaTher Holdings
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: PharmaTher Holdings Ltd. is a specialty pharmaceutical company focused on developing and commercializing pharmaceuticals with novel delivery methods to improve patient outcomes, with a market cap of CA$19.47 million.
Operations: PharmaTher Holdings Ltd. has not reported any specific revenue segments.
Market Cap: CA$19.47M
PharmaTher Holdings Ltd., with a market cap of CA$19.47 million, is pre-revenue and unprofitable, having reported a net loss for the first quarter ending August 31, 2024. The company has no debt and its short-term assets exceed liabilities, but it faces less than a year of cash runway if current cash flow trends persist. Recent developments include an FDA post-complete letter clarification meeting scheduled following minor deficiencies in their ketamine drug application. Despite stable board experience and no shareholder dilution over the past year, its share price remains highly volatile compared to most Canadian stocks.
-
Take a closer look at PharmaTher Holdings' potential here in our financial health report.
-
Learn about PharmaTher Holdings' historical performance here.
EMX Royalty
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: EMX Royalty Corporation, along with its subsidiaries, focuses on exploring and generating royalties from metals and minerals properties, with a market cap of CA$268.39 million.